B4T2 001
Alternative Names: Autologous CAR T cell therapy - Bio4t2; B4T2-001Latest Information Update: 19 Oct 2023
At a glance
- Originator Bio4t2
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Oct 2023 Efficacy data from a phase I trial in Solid tumours released by Bio4t2
- 10 Oct 2023 Shanghai East Hospital in collaboration with Bio4T2 initiated a phase-I trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in China (IV) (NCT06072989)
- 27 Jun 2023 Bio4t2 plans a phase II trial for Solid tumours in an unknown location (IV) in 2026 (Bio4t2 Pipeline, June 2023)